Related Experiment Video
Updated: Jun 16, 2026
05:45
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
Published on: April 5, 2019
Serum uric acid levels and neuromyelitis optica
Fuhua Peng1, Xiufeng Zhong, Xuhui Deng
1Department Of Neurology, The Third Affiliated Hospital, Sun Yat-Sen University, 510630 Guangzhou, Guangdong, China. pfh93@21cn.com
Journal of Neurology
|January 23, 2010
Summary
Serum uric acid (UA) is reduced in neuromyelitis optica (NMO) patients compared to healthy controls and those with cerebral infarction. This study investigated UA levels in NMO, finding no correlation with disease activity or disability.
Area of Science:
- Neurology
- Immunology
- Biochemistry
Background:
- Reduced serum uric acid (UA) levels are observed in multiple sclerosis (MS) and optic neuritis (ON).
- The relationship between serum UA and neuromyelitis optica (NMO), a distinct neurological condition, remains unexplored.
Purpose of the Study:
- To investigate the correlation between serum UA levels and clinical characteristics in patients with NMO.
- To compare serum UA levels in NMO patients with those in MS, ON, cerebral infarction (CI), and healthy controls (CTL).
Main Methods:
- Serum UA levels were measured in 403 Chinese participants, including 69 NMO patients.
- Participants comprised NMO, ON, MS, CI patients, and healthy controls.
- Statistical analysis was performed to compare UA levels across groups and correlate with clinical data.
Main Results:
- Serum UA levels were significantly lower in NMO patients compared to CI and CTL groups.
- No significant difference in UA levels was found between NMO and MS or NMO and ON groups.
- Serum UA levels in NMO were not correlated with MRI-defined disease activity, disability, or disease duration.
Conclusions:
- Patients with NMO exhibit reduced serum uric acid levels.
- Serum UA may serve as a potential biomarker in NMO, distinct from MS and ON.
- Further research is warranted to elucidate the role of UA in NMO pathogenesis.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...